By Carine Boustany, Ph.D., SVP, US Development Site Head and Global Head of Development Sciences, Boehringer Ingelheim
At Boehringer Ingelheim, we innovate ground-breaking medicines to address unmet medical needs with the purpose of helping patients’ overall lives and wellbeing today, tomorrow and for generations to come.
But a real threat is looming in Washington, and our innovation and all the innovation happening across the life science industry is in danger. The proposed legislation H.R. 3 risks government control of the availability of medicines, which would impede investment potential for the development of new medicines, treatments and potential cures for pervasive illnesses.